Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The rheumatic fever market is driven by a complex interaction of various factors that have an effect on the approach of health care industry towards this inflammation disease. Within the medical and pharmaceutical sectors, rheumatic fever (RF) which results from untreated streptococcal infections is both a challenge and an opportunity. Market forces are determined by various factors such as variation in prevalence, method of diagnosis, treatment options available, research initiatives and economic considerations.
The prevalence of rheumatic fever is one of the key determinants of market dynamics. Although there has been decline in number cases of this condition in many developed nations, it remains a major public health problem in some regions where access to healthcare is limited and streptococcal infections are common. The market adjusts itself to different prevalence rates by modifying its diagnostic approaches and treatment strategies that are relevant for each population affected.
Diagnostic methods play a very important role in the market dynamics associated with rheumatic fever. Early and accurate diagnosis is vital for proper management and prevention from complications like rheumatic heart disease. Advances in diagnostic technology such as molecular testing, echocardiography and serological assays among others also affect the market. Better diagnostics lead to improved patient outcomes while also guiding the development of targeted therapies.
Market forces on rheumatic fever depend on treatment options with emphasis on symptom control as well as relapse prevention. Antibiotics particularly penicillin’s form the core drugs used to treat streptococcus as well as prevent subsequent development of RF disease. Netty teas cause relief from signs among them nonsteroidal anti-inflammatory drugs (NSAIDs). In response to research efforts aimed at developing more targeted therapies and addressing autoimmune aspects involved with RF; current markets show their concern.
Market forces for RF are significantly influenced by continuing research activities. Researchers’ collaborative efforts with health providers including drug manufacturers aim at enhancing understanding about possible causes or pathways for treating or managing such conditions. Once scientific discoveries occur that might assist in the development of new therapies and methods for preventing rheumatic fever, such findings will automatically be used to shape market forces.
Market dynamics of RF are influenced by economic factors such as healthcare spending and medical access. Cost of drugs, diagnostic tests and possible surgical interventions can affect patients’ chances of seeing a doctor. As for pharmaceutical companies and healthcare providers among other market participants; they should always take into account economic considerations when dealing with issues related to treatments for rheumatic fever.
Early detection mechanisms and preventive measures have an impact in the market dynamics through public health campaigns. Better understanding on streptococcal infections themselves as well as their timely management consequences among others has potential effects on patient outcomes. Thus, markets are responding to these moves by encouraging learning programs while at the same time advocating for policies aimed at promoting prevention programs and access to relevant health services.
Rheumatic Fever Market Highlights:
Global Rheumatic Fever Market Overview
Rheumatic Fever Market Size was valued at USD 0.23 Billion in 2023. The Global Rheumatic Fever industry is projected to grow from USD 0.36 Billion in 2024 to USD 1.37 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.82% during the forecast period (2024 - 2032).
Rheumatic fever is an autoimmune inflammatory disease which can develop as a complication of inadequately treated strep throat. Strep throat is a condition caused by group a Streptococcus bacterium. Rheumatic fever is common in the age group of 5 to 15 years, but adults can also have the condition. In certain cases, rheumatic fever can cause long-term damage to the heart and heart valves.
The increasing occurrences of strep throat and growing prevalence of rheumatic heart disease are expected to be the major drivers for the growth of the market during the forecast period. Moreover, increasing government expenditure for the healthcare sector contributes to the market growth. According to the World Health Organization (WHO) report published in April 2018, approximately 30 million people are affected by rheumatic heart disease globally.
Despite the drivers, lack of awareness about the condition and limited healthcare facilities in emerging economies may hamper the growth of the market during the assessment period.
Oakrum Pharma, LLC and ANI Pharmaceuticals announced in February 2022 that the FDA approved a generic version of Cystadane1 (betaine anhydrous for oral solution) Powder in a 180-gm bottle, which was granted Competitive Generic Therapy (CGT) of 180 days of exclusivity.
Viatris Inc., the parent to Mylan Pharmaceuticals Inc., disclosed this information in February 2022 when it got the FDA’s approval on its Abbreviated New Drug Application (ANDA) for Cyclosporine Ophthalmic Emulsion 0.05%, which is the First generic version of Allergan’s Restasis® to be approved. There are no legal or regulatory barriers, and the company started operating right away.
In June 2023, New Zealand’s Associate Minister of Health for Pacific Peoples launched a further initiative aimed at reducing rheumatic fever. MP Barbara Edmonds said almost two-thirds of all rheumatic fever cases were among Pacific people. The Rheumatic Fever Roadmap 2023 - 2028 has been unveiled by Edmonds in Auckland this week to prevent, identify and treat rheumatic fever from around Aotearoa. Rheumatic fever is an autoimmune condition, according to Te Whatu Ora – New Zealand’s health authority. If untreated, strep throat can lead to rheumatic fever in at-risk children and young adults.
The American Society of Echocardiography (ASE) issued a new guideline document called “Recommendations on the Comprehensive Use of Echocardiography in Diagnosing and Therapeutic Intervention for ARF/RHD: A Report from the American Society of Echocardiography” in January, Journal of American Society Echocardiography Volume ___ issue ___. It had twenty-five ASE International Alliance Partners endorsements as an article that had been published by these societies. Among them, there is also a revised edition published with the title Recommendations for the Use of Echocardiography in Evaluating Rheumatic Heart Disease by the American Society of Echocardiography, out of all being updated to 2007 and 2009 guideline documents on valvular regurgitation or stenosis etiology, one of which was “Recommendations for the Use of Echocardiography in the Evaluation of Rheumatic Heart Disease: A Report from the American Society of Echocardiography”, under update. This new guideline is comprehensive and covers all uses of RHD.
Rheumatic Fever Market Segment Insights
The global rheumatic fever market has been segmented into diagnosis, treatment, distribution channel, and end-user.
Rheumatic Fever Diagnosis Insights
The market on the basis of diagnosis has been segmented into physical exam, blood test, electrocardiogram, and echocardiogram.
Rheumatic Fever Treatment Insights
The market, by treatment, has been segmented into pharmacotherapy and others. The pharmacotherapy segment is further segmented into antibiotics, anti-inflammatory medication, anticonvulsant medication, and others. Further, the anti-inflammatory medication segment has been segmented into aspirin, naproxen, and others.
Rheumatic Fever Distribution Channel Insights
The market, by distribution channel, has been segmented into retail pharmacies, hospital pharmacies, and others.
Rheumatic Fever End-User Insights
On the basis of end-user, the market has been segmented into hospitals and clinics, diagnostic centers, and others.
Rheumatic Fever Regional Insights
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The rheumatic fever market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European rheumatic fever market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The rheumatic fever market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rheumatic fever market in the Middle East & Africa has been segmented into the Middle East and Africa.
Rheumatic Fever Market Top Key Players
Some of the key players in the global rheumatic fever market are:
- Bayer AG
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- F. Hoffman-La Roche Ltd.
- Novartis AG
- Pfizer, Inc.
- AstraZeneca
- Valeant Pharmaceuticals International, Inc.
- Eli Lilly and Company
Geographically, the Americas is anticipated to dominate the global rheumatic fever market owing to a well-developed healthcare sector, rising prevalence of cardiovascular diseases, and growing healthcare expenditure. According to the Centers for Disease Control and Prevention, approximately 610,000 people die of heart diseases in the US every year. Additionally, increasing awareness among the people regarding the disease and well-developed technology are likely to contribute to the growth of the market.
Europe is expected to hold the second largest position in the global rheumatic fever market. The market growth in this region is attributed to the growing prevalence of rheumatic heart disease, availability of funds for research, and increasing healthcare expenditure.
Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population, continuously developing economies, growing occurrences of rheumatic fever, and increasing government funding for the healthcare sector.
On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to a well-developed healthcare sector and growing government initiatives for rheumatic heart disease. For instance, according to the RHD Global Status Report, 2015 to 2017, Egypt’s Rheumatic Heart Disease (RHD) programme trained 300 cardiologists and 1,500 primary healthcare physicians in rheumatic heart disease management in 2015. However, the market in the African region is expected to propel owing to the rising prevalence of rheumatic heart disease and increasing government initiatives for the prevention of rheumatic fever.
Rheumatic Fever Market Segment Analysis
Rheumatic Fever Diagnosis Outlook
- Physical Exam
- Blood Test
- Electrocardiogram
- Echocardiogram
Rheumatic Fever Treatment Outlook
- Pharmacotherapy
- Antibiotics
- Anti-inflammatory Medication
- Aspirin
- Naproxen
- Others
- Anticonvulsant Medication
- Others
- Others
Rheumatic Fever Distribution Channel Outlook
- Retail Pharmacies
- Hospital Pharmacies
- Others
Rheumatic Fever End-User Outlook
- Hospitals and Clinics
- Diagnostic Centers
- Others
Rheumatic Fever Regional Outlook
- Americas
-
- North America
- US
- Canada
- South America
- Europe
-
- Western Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Western Europe
- Eastern Europe
- Asia-Pacific
-
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
-
- Middle East
- Africa
Intended Audience
- Pharmaceutical Companies
- Research and Development (R&D) Companies
- Diagnostic Laboratories
- Government Research Institute
- Academic Institutes and Universities
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
